Literature DB >> 24655641

Management of tardive syndromes with clozapine: a case series.

Sandeep Grover1, Nandita Hazari2, Natasha Kate2, Kaustav Chakraborty2, Akhilesh Sharma2, Dharmendra Singh2, Jyoti Gupta2, Sanjay Lahariya2.   

Abstract

Tardive syndromes are among the most debilitating side effects associated with use of antipsychotics. In this case series we present 5 cases of drug induced tardive syndromes, who had not responded to many of the other therapeutic measures but responded to clozapine. The response rate with clozapine varied from 50% to 100% and the response was seen by week 3 in most cases. Over the long term follow-up of as long as 6 years the response to clozapine was sustained. In two cases clozapine could be stopped.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clozapine; Tardive dyskinesia; Tardive dystonia; Tardive syndromes

Mesh:

Substances:

Year:  2014        PMID: 24655641     DOI: 10.1016/j.ajp.2013.12.016

Source DB:  PubMed          Journal:  Asian J Psychiatr        ISSN: 1876-2018


  4 in total

Review 1.  A systematic review on the use of clozapine in treatment of tardive dyskinesia and tardive dystonia in patients with psychiatric disorders.

Authors:  Jocelyn Wong; Tiffanie Pang; Natalie Kwok Wing Cheuk; Yingqi Liao; Tarun Bastiampillai; Sherry Kit Wa Chan
Journal:  Psychopharmacology (Berl)       Date:  2022-09-30       Impact factor: 4.415

2.  [Antipsychotic-induced motor symptoms in schizophrenic psychoses-Part 3 : Tardive dyskinesia].

Authors:  D Hirjak; K M Kubera; S Bienentreu; P A Thomann; R C Wolf
Journal:  Nervenarzt       Date:  2019-05       Impact factor: 1.214

Review 3.  An Update on the Treatment of Chorea.

Authors:  Erin Feinstein; Ruth Walker
Journal:  Curr Treat Options Neurol       Date:  2018-09-25       Impact factor: 3.598

4.  Positive response to clozapine augmentation in a patient with obsessive-compulsive disorder complicated by a tardive movement disorder.

Authors:  Trino Baptista; José de Leon
Journal:  Braz J Psychiatry       Date:  2018-06       Impact factor: 2.697

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.